EZH2 and colitis: We then wondered whether another EZH2 inhibitor, GSK126, which is currently being evaluated in clinical trials to treat cancer (ClinicalTrials.gov identifier: NCT02082977)24, can exert effects on DSS-induced colitis similar to those observed with GSK343.